In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models
- Autores
- Ruiz, María Carolina; Resasco, Agustina; Di Virgilio, Ana Laura; Ayala, Miguel Ángel; Cavaco, Isabel; Cabrera, Silvia; Alemán, José; León, Ignacio Esteban
- Año de publicación
- 2019
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Platinum-based drugs, mainly cisplatin, are used for the treatment of several solid tumors such as OS. However, cisplatin treatment often results in the development of chemoresistance, leading therapeutic failure. We have previously reported that platinum complexes containing 8-hydroxyquinoline ligands have good antitumor activity against different cancer cell lines and with a different and better cytotoxic profile than cisplatin. Here, the anticancer properties of two different quinoline–platinum complexes [Pt(Cl)₂(quinoline)(dmso)] (1) [PtCl(8-O-quinoline)(dmso)] (2) on in vitro (2D and 3D) and in vivo models (xenograft tumor of human osteosarcoma in mice) are presented. In this order, [PtCl(8-O-quinoline)(dmso)] (2) impaired cell viability to have a more pronounced antitumor effect than cisplatin on MG-63 osteosarcoma cells (IC₅₀ 4 µM vs. 39 µM). Besides, [PtCl(8-O-quinoline)(dmso)] (2) increased ROS production in a dose-manner response and this compound induced early and late apoptotic fractions of human osteosarcoma cells. Finally, [PtCl(8-O-quinoline)(dmso)] (2) decreased the cell viability of multicellular spheroids and reduced the tumor volume on athymic nude mice N:NIH(S) Fox1nu without inducing side effects. In this way, [PtCl(8-O-quinoline)(dmso)] (2) did not alter the normal cytoarchitecture of liver and kidney and the blood biomarkers (GPT, GOT, uremia, and creatinine) did not suffer modifications. Taken together, our data indicate that these compounds showed a better anticancer performance than cisplatin on in vitro and in vivo studies. These results showed the importance of chelation in the antitumor properties, suggesting that the [PtCl(8-O-quinoline)(dmso)] (2) might be a promising agent for the treatment of human osteosarcoma tumors resistant to cisplatin.
Facultad de Ciencias Exactas
Centro de Química Inorgánica
Facultad de Ciencias Veterinarias - Materia
-
Química
Veterinaria
Platinum
Osteosarcoma
Spheroids
Apoptosis - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- http://creativecommons.org/licenses/by-nc-sa/4.0/
- Repositorio
- Institución
- Universidad Nacional de La Plata
- OAI Identificador
- oai:sedici.unlp.edu.ar:10915/131150
Ver los metadatos del registro completo
id |
SEDICI_2e92187e6f7c470c66bfe30b522d4b43 |
---|---|
oai_identifier_str |
oai:sedici.unlp.edu.ar:10915/131150 |
network_acronym_str |
SEDICI |
repository_id_str |
1329 |
network_name_str |
SEDICI (UNLP) |
spelling |
In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma modelsRuiz, María CarolinaResasco, AgustinaDi Virgilio, Ana LauraAyala, Miguel ÁngelCavaco, IsabelCabrera, SilviaAlemán, JoséLeón, Ignacio EstebanQuímicaVeterinariaPlatinumOsteosarcomaSpheroidsApoptosisPlatinum-based drugs, mainly cisplatin, are used for the treatment of several solid tumors such as OS. However, cisplatin treatment often results in the development of chemoresistance, leading therapeutic failure. We have previously reported that platinum complexes containing 8-hydroxyquinoline ligands have good antitumor activity against different cancer cell lines and with a different and better cytotoxic profile than cisplatin. Here, the anticancer properties of two different quinoline–platinum complexes [Pt(Cl)₂(quinoline)(dmso)] (1) [PtCl(8-O-quinoline)(dmso)] (2) on in vitro (2D and 3D) and in vivo models (xenograft tumor of human osteosarcoma in mice) are presented. In this order, [PtCl(8-O-quinoline)(dmso)] (2) impaired cell viability to have a more pronounced antitumor effect than cisplatin on MG-63 osteosarcoma cells (IC₅₀ 4 µM vs. 39 µM). Besides, [PtCl(8-O-quinoline)(dmso)] (2) increased ROS production in a dose-manner response and this compound induced early and late apoptotic fractions of human osteosarcoma cells. Finally, [PtCl(8-O-quinoline)(dmso)] (2) decreased the cell viability of multicellular spheroids and reduced the tumor volume on athymic nude mice N:NIH(S) Fox1<sup>nu</sup> without inducing side effects. In this way, [PtCl(8-O-quinoline)(dmso)] (2) did not alter the normal cytoarchitecture of liver and kidney and the blood biomarkers (GPT, GOT, uremia, and creatinine) did not suffer modifications. Taken together, our data indicate that these compounds showed a better anticancer performance than cisplatin on in vitro and in vivo studies. These results showed the importance of chelation in the antitumor properties, suggesting that the [PtCl(8-O-quinoline)(dmso)] (2) might be a promising agent for the treatment of human osteosarcoma tumors resistant to cisplatin.Facultad de Ciencias ExactasCentro de Química InorgánicaFacultad de Ciencias Veterinarias2019-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf681-692http://sedici.unlp.edu.ar/handle/10915/131150enginfo:eu-repo/semantics/altIdentifier/issn/1432-0843info:eu-repo/semantics/altIdentifier/issn/0344-5704info:eu-repo/semantics/altIdentifier/doi/10.1007/s00280-019-03773-xinfo:eu-repo/semantics/altIdentifier/pmid/30661096info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-10-15T11:23:33Zoai:sedici.unlp.edu.ar:10915/131150Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-10-15 11:23:34.121SEDICI (UNLP) - Universidad Nacional de La Platafalse |
dc.title.none.fl_str_mv |
In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models |
title |
In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models |
spellingShingle |
In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models Ruiz, María Carolina Química Veterinaria Platinum Osteosarcoma Spheroids Apoptosis |
title_short |
In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models |
title_full |
In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models |
title_fullStr |
In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models |
title_full_unstemmed |
In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models |
title_sort |
In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models |
dc.creator.none.fl_str_mv |
Ruiz, María Carolina Resasco, Agustina Di Virgilio, Ana Laura Ayala, Miguel Ángel Cavaco, Isabel Cabrera, Silvia Alemán, José León, Ignacio Esteban |
author |
Ruiz, María Carolina |
author_facet |
Ruiz, María Carolina Resasco, Agustina Di Virgilio, Ana Laura Ayala, Miguel Ángel Cavaco, Isabel Cabrera, Silvia Alemán, José León, Ignacio Esteban |
author_role |
author |
author2 |
Resasco, Agustina Di Virgilio, Ana Laura Ayala, Miguel Ángel Cavaco, Isabel Cabrera, Silvia Alemán, José León, Ignacio Esteban |
author2_role |
author author author author author author author |
dc.subject.none.fl_str_mv |
Química Veterinaria Platinum Osteosarcoma Spheroids Apoptosis |
topic |
Química Veterinaria Platinum Osteosarcoma Spheroids Apoptosis |
dc.description.none.fl_txt_mv |
Platinum-based drugs, mainly cisplatin, are used for the treatment of several solid tumors such as OS. However, cisplatin treatment often results in the development of chemoresistance, leading therapeutic failure. We have previously reported that platinum complexes containing 8-hydroxyquinoline ligands have good antitumor activity against different cancer cell lines and with a different and better cytotoxic profile than cisplatin. Here, the anticancer properties of two different quinoline–platinum complexes [Pt(Cl)₂(quinoline)(dmso)] (1) [PtCl(8-O-quinoline)(dmso)] (2) on in vitro (2D and 3D) and in vivo models (xenograft tumor of human osteosarcoma in mice) are presented. In this order, [PtCl(8-O-quinoline)(dmso)] (2) impaired cell viability to have a more pronounced antitumor effect than cisplatin on MG-63 osteosarcoma cells (IC₅₀ 4 µM vs. 39 µM). Besides, [PtCl(8-O-quinoline)(dmso)] (2) increased ROS production in a dose-manner response and this compound induced early and late apoptotic fractions of human osteosarcoma cells. Finally, [PtCl(8-O-quinoline)(dmso)] (2) decreased the cell viability of multicellular spheroids and reduced the tumor volume on athymic nude mice N:NIH(S) Fox1<sup>nu</sup> without inducing side effects. In this way, [PtCl(8-O-quinoline)(dmso)] (2) did not alter the normal cytoarchitecture of liver and kidney and the blood biomarkers (GPT, GOT, uremia, and creatinine) did not suffer modifications. Taken together, our data indicate that these compounds showed a better anticancer performance than cisplatin on in vitro and in vivo studies. These results showed the importance of chelation in the antitumor properties, suggesting that the [PtCl(8-O-quinoline)(dmso)] (2) might be a promising agent for the treatment of human osteosarcoma tumors resistant to cisplatin. Facultad de Ciencias Exactas Centro de Química Inorgánica Facultad de Ciencias Veterinarias |
description |
Platinum-based drugs, mainly cisplatin, are used for the treatment of several solid tumors such as OS. However, cisplatin treatment often results in the development of chemoresistance, leading therapeutic failure. We have previously reported that platinum complexes containing 8-hydroxyquinoline ligands have good antitumor activity against different cancer cell lines and with a different and better cytotoxic profile than cisplatin. Here, the anticancer properties of two different quinoline–platinum complexes [Pt(Cl)₂(quinoline)(dmso)] (1) [PtCl(8-O-quinoline)(dmso)] (2) on in vitro (2D and 3D) and in vivo models (xenograft tumor of human osteosarcoma in mice) are presented. In this order, [PtCl(8-O-quinoline)(dmso)] (2) impaired cell viability to have a more pronounced antitumor effect than cisplatin on MG-63 osteosarcoma cells (IC₅₀ 4 µM vs. 39 µM). Besides, [PtCl(8-O-quinoline)(dmso)] (2) increased ROS production in a dose-manner response and this compound induced early and late apoptotic fractions of human osteosarcoma cells. Finally, [PtCl(8-O-quinoline)(dmso)] (2) decreased the cell viability of multicellular spheroids and reduced the tumor volume on athymic nude mice N:NIH(S) Fox1<sup>nu</sup> without inducing side effects. In this way, [PtCl(8-O-quinoline)(dmso)] (2) did not alter the normal cytoarchitecture of liver and kidney and the blood biomarkers (GPT, GOT, uremia, and creatinine) did not suffer modifications. Taken together, our data indicate that these compounds showed a better anticancer performance than cisplatin on in vitro and in vivo studies. These results showed the importance of chelation in the antitumor properties, suggesting that the [PtCl(8-O-quinoline)(dmso)] (2) might be a promising agent for the treatment of human osteosarcoma tumors resistant to cisplatin. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-04 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Articulo http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://sedici.unlp.edu.ar/handle/10915/131150 |
url |
http://sedici.unlp.edu.ar/handle/10915/131150 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/issn/1432-0843 info:eu-repo/semantics/altIdentifier/issn/0344-5704 info:eu-repo/semantics/altIdentifier/doi/10.1007/s00280-019-03773-x info:eu-repo/semantics/altIdentifier/pmid/30661096 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
dc.format.none.fl_str_mv |
application/pdf 681-692 |
dc.source.none.fl_str_mv |
reponame:SEDICI (UNLP) instname:Universidad Nacional de La Plata instacron:UNLP |
reponame_str |
SEDICI (UNLP) |
collection |
SEDICI (UNLP) |
instname_str |
Universidad Nacional de La Plata |
instacron_str |
UNLP |
institution |
UNLP |
repository.name.fl_str_mv |
SEDICI (UNLP) - Universidad Nacional de La Plata |
repository.mail.fl_str_mv |
alira@sedici.unlp.edu.ar |
_version_ |
1846064290524561408 |
score |
13.22299 |